Monograph

The Ministry of Health’s Drug Advisory Committee has not recommended:

• Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and
• Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture

due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.

Teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.

MAF assistance does not apply to other brand(s), formulation(s) or strengths(s) of teriparatide for treating osteoporosis.